Third, despite comprehensive adjustment, residual and unmeasured confounding cannot be excluded—particularly limited information on medication use (including antiplatelet/anticoagulant therapy, statins, or renin–angiotensin system), inflammatory markers, treatment intensity, and adherence to CKD/PAD management and lifestyle interventions. This evidence concerns the gene REN and peripheral arterial disease.